Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas. more
Time Frame | ALRN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.73% | -2.27% | -0.57% |
1-Month Return | -36.69% | -3.96% | 1.21% |
3-Month Return | -17.52% | -9.7% | 7.57% |
6-Month Return | -30.46% | -3.37% | 11.45% |
1-Year Return | -9.24% | 3.71% | 28.48% |
3-Year Return | -79.55% | 3.8% | 29.52% |
5-Year Return | -77.06% | 39.78% | 90.66% |
10-Year Return | -98.95% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 155.00K | 163.00K | 121.00K | 169.00K | 119.00K | [{"date":"2019-12-31","value":91.72,"profit":true},{"date":"2020-12-31","value":96.45,"profit":true},{"date":"2021-12-31","value":71.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.41,"profit":true}] |
Gross Profit | (155.00K) | (163.00K) | (121.00K) | (169.00K) | (119.00K) | [{"date":"2019-12-31","value":-15500000,"profit":false},{"date":"2020-12-31","value":-16300000,"profit":false},{"date":"2021-12-31","value":-12100000,"profit":false},{"date":"2022-12-31","value":-16900000,"profit":false},{"date":"2023-12-31","value":-11900000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 29.96M | 20.50M | 26.61M | 27.65M | 16.28M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.42,"profit":true},{"date":"2021-12-31","value":88.81,"profit":true},{"date":"2022-12-31","value":92.29,"profit":true},{"date":"2023-12-31","value":54.33,"profit":true}] |
Operating Income | (29.96M) | (20.50M) | (26.61M) | (27.65M) | (16.28M) | [{"date":"2019-12-31","value":-2995600000,"profit":false},{"date":"2020-12-31","value":-2049600000,"profit":false},{"date":"2021-12-31","value":-2660500000,"profit":false},{"date":"2022-12-31","value":-2764700000,"profit":false},{"date":"2023-12-31","value":-1627600000,"profit":false}] |
Total Non-Operating Income/Expense | 1.17M | (470.00K) | - | 618.00K | 986.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-40.03,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":52.64,"profit":true},{"date":"2023-12-31","value":83.99,"profit":true}] |
Pre-Tax Income | (29.37M) | (21.16M) | (26.20M) | (27.33M) | (15.73M) | [{"date":"2019-12-31","value":-2936900000,"profit":false},{"date":"2020-12-31","value":-2115700000,"profit":false},{"date":"2021-12-31","value":-2620500000,"profit":false},{"date":"2022-12-31","value":-2732900000,"profit":false},{"date":"2023-12-31","value":-1573200000,"profit":false}] |
Income Taxes | (587.00K) | 661.00K | (441.00K) | (318.00K) | 928.00K | [{"date":"2019-12-31","value":-63.25,"profit":false},{"date":"2020-12-31","value":71.23,"profit":true},{"date":"2021-12-31","value":-47.52,"profit":false},{"date":"2022-12-31","value":-34.27,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (28.78M) | (21.82M) | - | (27.01M) | (16.66M) | [{"date":"2019-12-31","value":-2878200000,"profit":false},{"date":"2020-12-31","value":-2181800000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-2701100000,"profit":false},{"date":"2023-12-31","value":-1666000000,"profit":false}] |
Income From Continuous Operations | (29.37M) | (21.16M) | (26.16M) | (27.33M) | (12.94M) | [{"date":"2019-12-31","value":-2936900000,"profit":false},{"date":"2020-12-31","value":-2115700000,"profit":false},{"date":"2021-12-31","value":-2616400000,"profit":false},{"date":"2022-12-31","value":-2732900000,"profit":false},{"date":"2023-12-31","value":-1294000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (28.78M) | (21.82M) | (25.76M) | (27.01M) | (15.73M) | [{"date":"2019-12-31","value":-2878200000,"profit":false},{"date":"2020-12-31","value":-2181800000,"profit":false},{"date":"2021-12-31","value":-2576400000,"profit":false},{"date":"2022-12-31","value":-2701100000,"profit":false},{"date":"2023-12-31","value":-1573200000,"profit":false}] |
EPS (Diluted) | (25.80) | (12.60) | (5.80) | (6.02) | (3.38) | [{"date":"2019-12-31","value":-2580,"profit":false},{"date":"2020-12-31","value":-1260,"profit":false},{"date":"2021-12-31","value":-580,"profit":false},{"date":"2022-12-31","value":-602,"profit":false},{"date":"2023-12-31","value":-338,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALRN | |
---|---|
Cash Ratio | 3.12 |
Current Ratio | 3.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALRN | |
---|---|
ROA (LTM) | -25.86% |
ROE (LTM) | -44.32% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALRN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.52 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALRN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.97 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Aileron Therapeutics Inc (ALRN) share price today is $2.26
Yes, Indians can buy shares of Aileron Therapeutics Inc (ALRN) on Vested. To buy Aileron Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALRN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Aileron Therapeutics Inc (ALRN) via the Vested app. You can start investing in Aileron Therapeutics Inc (ALRN) with a minimum investment of $1.
You can invest in shares of Aileron Therapeutics Inc (ALRN) via Vested in three simple steps:
The 52-week high price of Aileron Therapeutics Inc (ALRN) is $7.42. The 52-week low price of Aileron Therapeutics Inc (ALRN) is $1.61.
The price-to-earnings (P/E) ratio of Aileron Therapeutics Inc (ALRN) is
The price-to-book (P/B) ratio of Aileron Therapeutics Inc (ALRN) is 0.97
The dividend yield of Aileron Therapeutics Inc (ALRN) is 0.00%
The market capitalization of Aileron Therapeutics Inc (ALRN) is $45.93M
The stock symbol (or ticker) of Aileron Therapeutics Inc is ALRN